JOURNAL OF CELLULAR PHYSIOLOGY, published by Wiley, is a leading peer-reviewed journal that has been at the forefront of cellular research since its inception in 1945. With its prestigious Q1 and Q2 rankings in the fields of Clinical Biochemistry and Cell Biology, this journal is highly regarded within the scientific community, reflecting its significant impact factor and rigorous peer-review process. Addressing the intricacies of cell function and physiology, it serves as a crucial resource for researchers, professionals, and students dedicated to advancing knowledge in the life sciences. The journal publishes cutting-edge research articles, integral reviews, and significant findings that bridge basic biology and clinical applications, ensuring access to high-quality scholarly content that informs current practices and future research directions. Although not open access, the journal maintains a rich archive of studies, making it an essential reference point for those invested in the health and biological sciences.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, published by Academic Press Inc Elsevier Science, stands as a leading periodical in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an ISSN of 0006-291X and an E-ISSN of 1090-2104, this esteemed journal has been a pivotal platform for the dissemination of groundbreaking research since its inception in 1959, continuing to publish influential findings through at least 2024. It holds a commendable Q2 ranking in Biochemistry and Q1 status in Biophysics as of 2023, reflecting its high impact and relevance in the field, supported by its strong Scopus rankings—ranking #43 in Biophysics and maintaining a presence in the top quartiles of several related categories. Although it is not an open-access journal, it provides critical insights and essential data that cater to researchers, professionals, and students keen on advancing their understanding of complex biochemical and biophysical processes. Its significant contributions to the scientific community underscore the importance of this journal as a reference point for innovative research and collaborative discourse.

TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, a reputable journal published by GAKUSHIN PUBL CO, serves as an essential resource for researchers and professionals engaged in the evolving fields of glycoscience and glyotechnology. Established in 1989, this journal has progressively focused on stimulating discussions and disseminating pivotal findings that impact various applications in biochemistry and organic chemistry. With an impressive converge covering decades up to 2024, the journal has carved a niche within the scientific community, despite currently being classified in the lower quartiles (Q4) for its respective categories in 2023. This designation underscores the potential for growth and enhanced visibility within research networks. While it currently operates under a subscription-based model, TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY remains committed to fostering innovation and interdisciplinary collaboration, providing a critical platform for the exploration of glycan structures and functions. Located in Tokyo, Japan, the journal invites contributions that contribute to the future direction of glycoscientific research and its applications.

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

The EMBO JOURNAL, published by Wiley in Germany, is a renowned scientific journal that has been at the forefront of research in the fields of biochemistry, genetics, and molecular biology since its inception in 1982. With an impressive convergence of contributions leading up to 2024, this journal is recognized for its high impact, reflected in its Q1 rankings across multiple categories including Immunology, Molecular Biology, and Neuroscience. It holds a prestigious place in the academic community, standing out with an exemplary Scopus ranking of #3 in General Immunology and Microbiology and #6 in General Neuroscience, making it a critical resource for researchers, professionals, and students alike. The journal aims to publish transformative research that sheds light on the underlying mechanisms of biological processes, thus advancing our understanding of health and disease. While currently not offering open access, the EMBO JOURNAL continues to facilitate a rich exchange of knowledge through its rigorous peer-review process and commitment to excellence.

Biochemistry and Biophysics Reports, published by Elsevier, serves as a vital platform for the dissemination of innovative research in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an Open Access model initiated in 2015, this journal aims to facilitate the unimpeded sharing of knowledge, allowing researchers, professionals, and students free access to significant findings and developments. The journal has established a presence in the academic community, currently holding a Q3 ranking in Biochemistry, Q2 in Biophysics, alongside its Q3 standings in both Cell Biology and Molecular Biology categories for 2023. These metrics underscore its commitment to quality and relevance, garnering attention with Scopus ranks reflecting its emerging influence. Located in the Netherlands, Biochemistry and Biophysics Reports continues to foster dialogue and collaboration among the scientific community through high-quality research outputs, contributing to advancements in understanding the intricate biochemical processes and biophysical principles that underpin life sciences.